We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Critical Final Step in Parthanatos Pathway Identified

By LabMedica International staff writers
Posted on 18 Oct 2016
A team of neurological disease researchers has identified the enzyme responsible for the last link in a chain of molecular steps that constitutes the cell death pathway called parthanatos.

Parthanatos is a form of programmed cell death that is distinct from other cell death processes such as necrosis and apoptosis. More...
While necrosis is caused by acute cell injury resulting in traumatic cell death, and apoptosis is a highly controlled process signaled by apoptotic intracellular signals, parthanatos is caused by the accumulation of PAR (Poly(ADP-ribose)) and the nuclear translocation of apoptosis-inducing factor (AIF) from mitochondria. Parthanatos is also known as PARP-1 dependent cell death. The PARP-1 (Poly(ADP-ribose) polymerase-1) enzyme mediates parthanatos under circumstances in which it becomes over-activated in response to extreme genomic stress and synthesizes PAR, which causes nuclear translocation of AIF. Parthanatos is involved in several well-known diseases including Parkinson’s disease, stroke, heart attack, and diabetes.

Investigators at Johns Hopkins University (Baltimore, MD, USA) reported in the October 7, 2016, issue of the journal Science that they had used two sequential unbiased screens, including a human protein array and a small interfering RNA screen to discover that macrophage migration inhibitory factor (MIF) bound AIF and was required for parthanatos. In the presence of magnesium or calcium ions, MIF possessed both 3′ exonuclease and endonuclease activity. It bound to 5′ unpaired bases of single-stranded DNA with stem loop structure and cleaved its 3′ unpaired bases. These nuclease activities allowed MIF to cleave genomic DNA into large fragments.

Depletion of MIF markedly reduced cell death induced by N-methyl-d-aspartate (NMDA) receptor–activated glutamate toxicity in primary neuronal cultures as well as DNA damage caused by N-methyl-N′-nitro-N-nitrosoguanidine (MNNG) or focal stroke in mice. Mutating key amino acid residues in the nuclease domain of MIF eliminated its nuclease activity and prevented parthanatos. In addition, disrupting the AIF and MIF interaction prevented the translocation of MIF from the cytosol to the nucleus and protected against parthanatos. . Therefore, targeting MIF nuclease activity may offer an important therapeutic opportunity for a variety of disorders with excessive PARP-1 activation.

"We found that AIF binds to MIF and carries it into the nucleus, where MIF chops up DNA," said senior author Dr. Ted Dawson, director of the institute for cell engineering at Johns Hopkins University. "We think that is the final execution step in parthanatos. I cannot overemphasize what an important form of cell death it is; it plays a role in almost all forms of cellular injury. We are interested in finding out whether MIF is also involved in Parkinson's, Alzheimer's, and other neurodegenerative diseases. If so, and if an inhibitor of MIF proves successful in testing, it could have implications for treating many conditions."

Related Links:
Johns Hopkins University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.